Trial · NCT03851705
Registered outcomes52
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 52
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150 | Baseline, Day 150 | Percentage Change in LDL-C levels from Baseline to Day 150 |
| Secondary | Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150 | Baseline, Day 150 | Absolute Change in LDL-C levels (mg/dL) from baseline to Day 150 |
| Secondary | Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 180 | Baseline, Days 90, 150, 180 | Percentage Change in LDL-C levels from baseline to subsequent visits on Days 90, 150, and 180 |
| Secondary | Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 720 | Baseline, Days 270, 330, 450, 510, 630, 690, and 720 | Percentage Change in LDL-C levels from baseline to subsequent visits up to Day 720 |
| Secondary | Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 180 | Baseline, Days 90, 150, 180 | Absolute change in LDL-C levels (mg/dL) from baseline to subsequent visits on Days 90, 150 and 180 based on the |
| Secondary | Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 720 | Baseline, Days 270, 330, 450, 510, 630, 690, and 720 | Absolute change in LDL-C levels from Baseline to Subsequent Visits up to Day 720 |
| Secondary | Percent Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 180 | Baseline, Days 90, 150, 180 | Percentage Change in PCSK9 from baseline to subsequent visits up to Day 180 |
| Secondary | Percent Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 720 | Baseline, Days 270, 330, 450, 510, 630, 690, and 720 | Percentage Change in PCSK9 from baseline to subsequent visits up to Day 720 |
| Secondary | Absolute Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 180 | Baseline, Days 90, 150, 180 | Absolute Change in PCSK9 from baseline to subsequent visits up to Day 180 |
| Secondary | Absolute Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 720 | Baseline, Days 270, 330, 450, 510, 630, 690, and 720 | Absolute Change in PCSK9 from baseline to subsequent visits up to Day 720 |
| Secondary | Percent Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 180 | Baseline, Days 90, 150 and 180 | Percentage change in total cholesterol from baseline to subsequent visits up to Day 180 |
| Secondary | Absolute Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 180 | Baseline, Days 90, 150, 180 | Absolute Change in total cholesterol from baseline to subsequent visits up to Day 180 |
| Secondary | Percent Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 720 | Baseline, Days 270, 330, 450, 510, 630, 690, and 720 | Percentage change in total cholesterol from baseline to subsequent visits up to Day 720 |
| Secondary | Absolute Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 720 | Baseline, Days 270, 330, 450, 510, 630, 690, and 720 | Absolute Change in total cholesterol from baseline to subsequent visits up to Day 720 |
| Secondary | Percent Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 180 | Baseline, Days 90, 150, 180 | Percentage change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 180 demonstrated by Mixed Model Repeated Measures statisitical method. |
| Secondary | Percent Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 720 | Baseline, Days 270, 330, 450, 510, 630, 690, and 720 | Percentage Change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 720 |
| Secondary | Absolute Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 180 | Baseline, Days 90, 150, 180 | Absolute change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 180 |
| Secondary | Absolute Change in Apolipoprotein B (Apo B) From Baseline to Subsequent Visits up to Day 720 | Baseline, Days 270, 330, 450, 510, 630, 690, and 720 | Absolute Change in Apolipoprotein B (Apo B) from baseline to subsequent visits up to Day 720 |
| Secondary | Percent Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 180 | Baseline, Days 90, 150, 180 | Percentage change in non-HDL-C levels from baseline to subsequent visits up to Day 180 |
| Secondary | Percent Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 720 | Baseline, Days 270, 330, 450, 510, 630, 690, and 720 | Percentage Change in non-HDL-C from Baseline to subsequent visits up to Day 720 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03851705/registered